Koh H K, Sober A J, Day C L, Lew R A, Kopf A W, Lamar W, Ben Cosimi A, Wood W C, Mihm M C, Malt R A
J Clin Oncol. 1986 Aug;4(8):1238-44. doi: 10.1200/JCO.1986.4.8.1238.
We tested 12 clinical and histologic variables to see which ones best predicted death from melanoma in 66 patients with positive elective regional node dissections (clinical stage I, pathologic stage II [CSI, PSII]). Despite the presence of lymph node metastases, not all patients had poor prognoses. Patients with tumors less than or equal to 3.5 mm and a percentage of positive nodes less than or equal to 20% had a 7-year survival rate of 66%. Within this low-risk group the subset with primary lesions on the trunk or extremities (except hands and feet) had a 7-year survival rate of 76%. This compares with poor 7-year survivals of 29% and 30% observed in other defined high-risk groups. Our results confirm and extend earlier observations concerning the prognoses of CSI, PSII melanoma patients and are relevant to any ongoing and future studies concerning elective regional node dissection (ERND) or adjuvant therapy trials in melanoma.
我们检测了12项临床和组织学变量，以确定哪些变量能最好地预测66例选择性区域淋巴结清扫阳性（临床I期，病理II期[CSI，PSII]）的黑色素瘤患者的死亡情况。尽管存在淋巴结转移，但并非所有患者的预后都很差。肿瘤小于或等于3.5毫米且阳性淋巴结百分比小于或等于20%的患者，其7年生存率为66%。在这个低风险组中，躯干或四肢（手和脚除外）有原发性病变的亚组，其7年生存率为76%。相比之下，在其他明确的高风险组中，观察到的7年生存率分别为29%和30%，情况较差。我们的结果证实并扩展了早期关于CSI、PSII黑色素瘤患者预后的观察结果，并且与任何正在进行的以及未来关于黑色素瘤选择性区域淋巴结清扫（ERND）或辅助治疗试验的研究相关。
